DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide first isolated in 1977 from rabbit cerebral venous blood and described as a delta-sleep-inducing agent. Despite over 45 years of intermittent research, no dedicated receptor, gene, or direct molecular binding partner has been identified for DSIP. The peptide remains one of the most biologically suggestive yet mechanistically opaque entries in the performance peptide literature — capable of modulating sleep architecture, thermoregulation, hormonal release, and pain thresholds, yet stubbornly resistant to classical receptor pharmacology. The proposed target for this fold, the GABA-A receptor complex (specifically its benzodiazepine/neurosteroid-modulated chloride channel), is a reasonable hypothesis derived from DSIP's sedative phenotype but has never been confirmed by radioligand displacement, patch-clamp electrophysiology, or any structural method. This absence of a confirmed, annotated molecular target is precisely what triggered the discard.

The modification rationale for Fold №62 is scientifically well-grounded. DSIP's two central glycines (positions 3 and 4) and overall lack of secondary structure mean the linear peptide samples an enormous conformational ensemble — a property that dilutes any productive binding pose and maximises entropy costs upon receptor engagement. Head-to-tail backbone cyclization, joining the Trp-1 α-amine to the Glu-9 α-carboxylate via a direct amide bond, represents the most radical conformational constraint achievable without introducing non-canonical residues: it forces backbone closure, dramatically restricts accessible φ/ψ space, and blocks both termini from exopeptidase recognition in a single chemical step. This strategy has precedent in the broader peptide field — somatostatin and its clinical analogues (octreotide, lanreotide) are the canonical example, where head-to-tail cyclization of a 14-mer yielded nanomolar potency and metabolic stability from a flexible, rapidly cleared linear precursor.

The fold sits within a coherent DSIP experimental narrative at this lab. Fold №46 (Ac-WAGGDASGE-NH₂, pLDDT 0.65, PROMISING) established that N-terminal acetylation combined with C-terminal amidation provides partial terminus protection and marginally improved predicted structure confidence — but the capping strategy is inherently incomplete because it does not constrain the backbone or close the conformational ensemble. Fold №57 attempted a more local geometric fix — Gly-3/Gly-4 → D-Ala double substitution — but was discarded, likely because point mutations at the Gly-Gly hinge are too local to globally constrain a 9-mer. Head-to-tail cyclization is the logical escalation: it addresses the global conformational problem that neither terminus capping nor D-Ala substitution could solve.

The literature base provides meaningful, if indirect, support. Kovalzon & Strekalova (2006) reported that artificial structural analogues of DSIP — not native DSIP itself — produced significant slow-wave sleep promotion in rabbits and rats. This is a critical observation: it implies the native linear, floppy conformation is suboptimal and that geometric constraint can unlock latent activity from this sequence. The clinical data of Schneider-Helmert (1984) showing dose-dependency and buildup effects are consistent with a peptide of marginal affinity limited by conformational entropy. Mu et al. (2024) demonstrated that dramatically improved CNS delivery (via a BBB-crossing fusion) substantially enhances DSIP efficacy in a validated insomnia model — suggesting intrinsic potency is a real bottleneck, which conformational preorganization is designed to address.

The structural prediction pipeline was never executed. The orchestrator's predictability gate requires a resolvable UniProt ID for the target before allocating compute to Boltz-2/Chai-1 complex modelling. DSIP's candidate target — the GABA-A receptor chloride channel complex — lacks a single canonical UniProt entry that maps cleanly to the benzodiazepine/neurosteroid modulatory site in the context of this peptide's hypothesized interaction mode. The gate correctly flagged this as target_not_predictable and halted the fold. No pLDDT, pTM, ipTM, or binding probability data were produced. Heuristic peptide property estimates were also not generated because the structural agent did not process the sequence.

It is important to emphasise what this discard does not mean. The cyclization chemistry is feasible — head-to-tail macrolactamisation of a 9-mer via standard solid-phase peptide synthesis with on-resin or solution-phase cyclization is well-established. The biological hypothesis — that pre-organizing a β-turn around the Gly-Gly hinge will improve target engagement — is not disproved. The DSIP literature's consistent finding that constrained analogues outperform native DSIP is, if anything, supportive. The discard reflects a limitation of our current in silico pipeline: it cannot evaluate peptide-target interactions when the target lacks a resolvable structural identity in the databases the tool queries. This is a tool boundary, not a verdict on the science.

Several challenges remain beyond the tool limitation. The breadth of DSIP's reported effects (sleep, thermoregulation, heart rate, pain, lymphokines, hormonal levels) suggests either extreme promiscuity or an indirect mechanism — neither is easily addressed by optimising binding to a single receptor. Head-to-tail cyclization imposes a specific macrocyclic geometry that may not match the true bioactive conformation, particularly if DSIP acts through a mode distinct from a single compact β-turn. The DSIP literature is also dominated by pre-genomics, pre-structural-biology studies from 1984–1988 whose basic pharmacological claims have not been systematically reproduced by contemporary methods. These are biological uncertainties that persist regardless of what any in silico tool returns.

The path forward for this hypothesis likely runs through two parallel tracks: synthetic and biophysical. On the synthetic side, the cyclic peptide is accessible and could be tested in a competitive radioligand displacement assay at the GABA-A benzodiazepine site, or in primary hippocampal or cortical neurons using whole-cell patch-clamp, before any further computational investment. On the computational side, if a cryo-EM structure of the GABA-A complex bound to a neurosteroid or small-molecule modulator is used as the target scaffold — bypassing the UniProt gate — a future fold could attempt to model the cyclic peptide interaction directly. Alternatively, a molecular dynamics simulation of the free macrocycle in explicit solvent would reveal whether the predicted β-turn is genuinely the dominant low-energy conformer, independent of any target.